118 related articles for article (PubMed ID: 2203852)
21. Clinical pharmacology of enalkiren, a novel, dipeptide renin inhibitor.
Glassman HN; Kleinert HD; Boger RS; Moyse DM; Griffiths AN; Luther RR
J Cardiovasc Pharmacol; 1990; 16 Suppl 4():S76-81. PubMed ID: 1705633
[TBL] [Abstract][Full Text] [Related]
22. Intraocular Pressure-Lowering Activity of NCX 470, a Novel Nitric Oxide-Donating Bimatoprost in Preclinical Models.
Impagnatiello F; Toris CB; Batugo M; Prasanna G; Borghi V; Bastia E; Ongini E; Krauss AH
Invest Ophthalmol Vis Sci; 2015 Oct; 56(11):6558-64. PubMed ID: 26457541
[TBL] [Abstract][Full Text] [Related]
23. Renin inhibitors containing new P1-P1' dipeptide mimetics with heterocycles in P1'.
Raddatz P; Jonczyk A; Minck KO; Rippmann F; Schittenhelm C; Schmitges CJ
J Med Chem; 1992 Sep; 35(19):3525-36. PubMed ID: 1404233
[TBL] [Abstract][Full Text] [Related]
24. Pharmacology of the intraocular pressure (IOP) lowering effect of systemic dexanabinol (HU-211), a non-psychotropic cannabinoid.
Beilin M; Neumann R; Belkin M; Green K; Bar-Ilan A
J Ocul Pharmacol Ther; 2000 Jun; 16(3):217-30. PubMed ID: 10872919
[TBL] [Abstract][Full Text] [Related]
25. Simultaneous modeling of the pharmacokinetic and pharmacodynamic properties of enalkiren (Abbott-64662, a renin inhibitor). II: A dose-ranging study in patients with congestive heart failure.
Gupta SK; Granneman GR; Packer M; Boger RS
J Cardiovasc Pharmacol; 1993 May; 21(5):834-40. PubMed ID: 7685457
[TBL] [Abstract][Full Text] [Related]
26. Haemodynamic, renal and hormonal responses to enalkiren in four patients with post-surgical oliguria.
Jackson B; Liu G; Perich RB; Paxton D; McNicols L; Gutteridge G; Johnston CI
Clin Exp Pharmacol Physiol; 1994 Feb; 21(2):163-6. PubMed ID: 8039272
[TBL] [Abstract][Full Text] [Related]
27. Hemodynamic effects of renin inhibition by enalkiren in chronic congestive heart failure.
Neuberg GW; Kukin ML; Penn J; Medina N; Yushak M; Packer M
Am J Cardiol; 1991 Jan; 67(1):63-6. PubMed ID: 1986506
[TBL] [Abstract][Full Text] [Related]
28. Effects of renin inhibition in systemic hypertension.
Anderson PW; Do YS; Schambelan M; Horton R; Boger RS; Luther RR; Hsueh WA
Am J Cardiol; 1990 Dec; 66(19):1342-7. PubMed ID: 2244565
[TBL] [Abstract][Full Text] [Related]
29. Effects of a topical alpha2 adrenergic agonist on ciliary blood flow and aqueous production in rabbits.
Reitsamer HA; Posey M; Kiel JW
Exp Eye Res; 2006 Mar; 82(3):405-15. PubMed ID: 16198336
[TBL] [Abstract][Full Text] [Related]
30. Ocular effects of topical administration of the phosphodiesterase III inhibitor milrinone in rabbits and cats.
Lee KC; Silver PJ; Bode DC; Gherezghiher T
Methods Find Exp Clin Pharmacol; 1993 Oct; 15(8):527-34. PubMed ID: 8309316
[TBL] [Abstract][Full Text] [Related]
31. Intrarenal angiotensin II formation in humans. Evidence from renin inhibition.
Fisher ND; Allan DR; Gaboury CL; Hollenberg NK
Hypertension; 1995 May; 25(5):935-9. PubMed ID: 7737730
[TBL] [Abstract][Full Text] [Related]
32. Topical nylidrin and aqueous humor dynamics in rabbits and monkeys.
Sobel L; Serle JB; Podos SM; Krupin T; Chubak GS; Yablonski ME; Severin C
Arch Ophthalmol; 1983 Aug; 101(8):1281-3. PubMed ID: 6882258
[TBL] [Abstract][Full Text] [Related]
33. Effects of a renin inhibitor, SR 43845, and of captopril on blood pressure and plasma active renin in conscious sodium-replete macaca.
Lacour C; Cazaubon C; Roccon A; Segondy D; Wagnon J; Nisato D
J Hypertens Suppl; 1989 Apr; 7(2):S33-5. PubMed ID: 2666612
[TBL] [Abstract][Full Text] [Related]
34. An orally active renin inhibitor: cyclohexylnorstatine-containing dipeptide (KRI-1314).
Miyazaki M; Etoh Y; Iizuka K; Toda N
J Hypertens Suppl; 1989 Apr; 7(2):S25-7. PubMed ID: 2666609
[TBL] [Abstract][Full Text] [Related]
35. Apraclonidine and brimonidine effects on anterior ocular and cardiovascular physiology in normal and sympathectomized monkeys.
Gabelt BT; Robinson JC; Hubbard WC; Peterson CM; Debink N; Wadhwa A; Kaufman PL
Exp Eye Res; 1994 Dec; 59(6):633-44. PubMed ID: 7698258
[TBL] [Abstract][Full Text] [Related]
36. Ocular hypotensive effect of 8-hydroxycarteolol, a metabolite of carteolol.
Sugiyama K; Enya T; Kitazawa Y
Int Ophthalmol; 1989 Jan; 13(1-2):85-9. PubMed ID: 2744958
[TBL] [Abstract][Full Text] [Related]
37. Acute hypotensive responses to peptide inhibitors of renin in conscious monkeys: an effect on blood pressure independent of plasma renin inhibition.
Schaffer LW; Schorn TW; Winquist RJ; Strouse JF; Payne L; Chakravarty PK; de Laszlo SE; tenBroeke J; Veber DF; Greenlee WJ
J Hypertens; 1990 Mar; 8(3):251-9. PubMed ID: 2159506
[TBL] [Abstract][Full Text] [Related]
38. Dipeptide glycols: a new class of renin inhibitors.
Hanson GJ; Baran JS; Lindberg T; Walsh GM; Papaioannou SE; Babler M; Bittner SE; Yang PC; Dal Corobbo M
Biochem Biophys Res Commun; 1985 Oct; 132(1):155-61. PubMed ID: 3933494
[TBL] [Abstract][Full Text] [Related]
39. Consequences of Puberty on Efficacy of Intraocular Pressure-Lowering Drugs in Male Dutch-Belted Rabbits.
Hays CL; Okafor KC; Fan S; High R; Singh DP; Toris CB
J Ocul Pharmacol Ther; 2018; 34(1-2):76-84. PubMed ID: 28820646
[TBL] [Abstract][Full Text] [Related]
40. Effects of latrunculin B on outflow facility, intraocular pressure, corneal thickness, and miotic and accommodative responses to pilocarpine in monkeys.
Okka M; Tian B; Kaufman PL
Trans Am Ophthalmol Soc; 2004; 102():251-7; discussion 257-9. PubMed ID: 15747763
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
